clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Lymphadenitis D008199 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Leprosy D007918 8 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Fistula D005402 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Holmberg SD and Moorman AC Possible bias of ascertainment in assessing chemoprophylaxis for cryptosporidiosis. 2001 AIDS pmid:11504998
Chaisson RE et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. 1997 AIDS pmid:9147422
Johnson RC et al. Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. 2002 AIDS pmid:12172103
Heald AE et al. Taste and smell complaints in HIV-infected patients. 1998 AIDS pmid:9764787
Macías J et al. Rhodococcus or mycobacterium? An example of misdiagnosis in HIV infection. 1997 AIDS pmid:9030376
Preston SL et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. 1998 AIDS pmid:9468380
Bayoumi AM and Redelmeier DA Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis. 1998 AIDS pmid:9727572
Fichtenbaum CJ et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. 2000 AIDS pmid:11153670
High-dose clarithromycin should be avoided. 1996 AIDS Alert pmid:11363723
Physician's aggressive preventive therapy differs. 1995 AIDS Alert pmid:11362774
New drug applications sought. 1995 AIDS Alert pmid:11362777
Researchers find new drugs to fight MAC. 1995 AIDS Alert pmid:11362925
Clarithromycin for MAC. 1995 AIDS Patient Care pmid:11361361
Rosales CM et al. AIDS presenting with cutaneous Kaposi's sarcoma and bacillary angiomatosis in the bone marrow mimicking Kaposi's sarcoma. 2002 AIDS Patient Care STDS pmid:12542930
Mah Ming JB and Gill MJ Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. 2003 AIDS Patient Care STDS pmid:12816614
Monno R et al. Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. 2001 AIDS Patient Care STDS pmid:11788074
Yangco BG et al. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? 2014 AIDS Patient Care STDS pmid:24833016
Desimone JA et al. Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. 2003 AIDS Patient Care STDS pmid:14746655
NIAID study rules out high-dose clarithromycin for AIDS-related MAC. 1996 AIDS Patient Care STDS pmid:11361534
New data suggest antibiotic clarithromycin is effective in prolonging life of AIDS patients. 1996 AIDS Patient Care STDS pmid:11361575
Clarithromycin and MAC. 1996 AIDS Patient Care STDS pmid:11361673
Different clarithromycin doses affect mortality. 1997 AIDS Patient Care STDS pmid:11361754
Aboulafia DM Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. 2003 AIDS Read pmid:14524324
Kahlon SS et al. Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. 2008 AIDS Read pmid:18975441
Chu J et al. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. 2011 AIDS Res Ther pmid:21388558
Smibert OC et al. Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. 2017 AIDS Res. Hum. Retroviruses pmid:28791872
Kuwayama H et al. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. 2007 Aliment. Pharmacol. Ther. pmid:17439512
Van Oijen AH et al. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. 2000 Aliment. Pharmacol. Ther. pmid:10930892
Gisbert JP et al. Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. 2003 Aliment. Pharmacol. Ther. pmid:12641497
Thijs JC et al. Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. 1994 Aliment. Pharmacol. Ther. pmid:8186339
Nada T et al. DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy. 2004 Aliment. Pharmacol. Ther. pmid:15298604
Adachi K et al. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. 2001 Aliment. Pharmacol. Ther. pmid:11472321
Paré P et al. Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. 1999 Aliment. Pharmacol. Ther. pmid:10468683
de Francesco V et al. Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. 2006 Aliment. Pharmacol. Ther. pmid:16423002
Lamouliatte H et al. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. 1999 Aliment. Pharmacol. Ther. pmid:10571611
Wong WM et al. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. 2002 Aliment. Pharmacol. Ther. pmid:11929398
Pazzi P et al. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. 1998 Aliment. Pharmacol. Ther. pmid:9726385
Harris AW et al. Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. 1998 Aliment. Pharmacol. Ther. pmid:9726387
Lee JM et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. 1999 Aliment. Pharmacol. Ther. pmid:10215733
Isomoto H et al. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. 2000 Aliment. Pharmacol. Ther. pmid:11121910
Canducci F et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. 2000 Aliment. Pharmacol. Ther. pmid:11121911
Pilotto A et al. Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. 1996 Aliment. Pharmacol. Ther. pmid:8971305
Kawabata H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. 2003 Aliment. Pharmacol. Ther. pmid:12534411
Catalano F et al. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. 2000 Aliment. Pharmacol. Ther. pmid:11012478
Breuer T et al. Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. 1997 Aliment. Pharmacol. Ther. pmid:9354204
De Francesco V et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. 2004 Aliment. Pharmacol. Ther. pmid:14871280
Koivisto TT et al. First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. 2005 Aliment. Pharmacol. Ther. pmid:15771764
Delchier JC et al. Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. 1996 Aliment. Pharmacol. Ther. pmid:8791948
Jaup BH and Norrby A Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection. 1996 Aliment. Pharmacol. Ther. pmid:8791950
Laine L et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. 1996 Aliment. Pharmacol. Ther. pmid:8971306